Why to avoid dual primary endpoints in cardiovascular trials

Introduction: In an adequately designed randomised controlled trial for confirming the efficacy of a new drug in patients with chronic heart failure (CHF), mortality (all-cause or cardiovascular) should usually be the primary endpoint – either alone or as a part of a composite endpoint with outcomes [for full text, please go to the a.m. URL]